These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 8816151

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Phase 1 trial of a 24-valent Klebsiella capsular polysaccharide vaccine and an eight-valent Pseudomonas O-polysaccharide conjugate vaccine administered simultaneously.
    Edelman R, Taylor DN, Wasserman SS, McClain JB, Cross AS, Sadoff JC, Que JU, Cryz SJ.
    Vaccine; 1994 Nov; 12(14):1288-94. PubMed ID: 7856293
    [Abstract] [Full Text] [Related]

  • 3. Safety and immunogenicity of Klebsiella pneumoniae K1 capsular polysaccharide vaccine in humans.
    Cryz SJ, Fürer E, Germanier R.
    J Infect Dis; 1985 Apr; 151(4):665-71. PubMed ID: 3882856
    [Abstract] [Full Text] [Related]

  • 4. Immunoprophylaxis against klebsiella and pseudomonas aeruginosa infections. The Federal Hyperimmune Immunoglobulin Trial Study Group.
    Donta ST, Peduzzi P, Cross AS, Sadoff J, Haakenson C, Cryz SJ, Kauffman C, Bradley S, Gafford G, Elliston D, Beam TR, John JF, Ribner B, Cantey R, Welsh CH, Ellison RT, Young EJ, Hamill RJ, Leaf H, Schein RM, Mulligan M, Johnson C, Abrutyn E, Griffiss JM, Slagle D.
    J Infect Dis; 1996 Sep; 174(3):537-43. PubMed ID: 8769611
    [Abstract] [Full Text] [Related]

  • 5. Octavalent Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine.
    Cryz SJ, Sadoff JC, Fürer E.
    Microb Pathog; 1989 Jan; 6(1):75-80. PubMed ID: 2733597
    [Abstract] [Full Text] [Related]

  • 6. Safety and immunogenicity of a polyvalent Klebsiella capsular polysaccharide vaccine in humans.
    Cryz SJ, Mortimer P, Cross AS, Fürer E, Germanier R.
    Vaccine; 1986 Mar; 4(1):15-20. PubMed ID: 3962447
    [Abstract] [Full Text] [Related]

  • 7. Heptavalent O-Antigen Bioconjugate Vaccine Exhibiting Differential Functional Antibody Responses Against Diverse Klebsiella pneumoniae Isolates.
    Wantuch PL, Knoot CJ, Robinson LS, Vinogradov E, Scott NE, Harding CM, Rosen DA.
    J Infect Dis; 2024 Sep 23; 230(3):578-589. PubMed ID: 38401891
    [Abstract] [Full Text] [Related]

  • 8. Human IgG and IgA subclass response following immunization with a polyvalent Klebsiella capsular polysaccharide vaccine.
    Cryz SJ, Cross AS, Sadoff GC, Que JU.
    Eur J Immunol; 1988 Dec 23; 18(12):2073-5. PubMed ID: 3220104
    [Abstract] [Full Text] [Related]

  • 9. Safety and immunogenicity of Staphylococcus aureus type 5 capsular polysaccharide-Pseudomonas aeruginosa recombinant exoprotein A conjugate vaccine in patients on hemodialysis.
    Welch PG, Fattom A, Moore J, Schneerson R, Shiloach J, Bryla DA, Li X, Robbins JB.
    J Am Soc Nephrol; 1996 Feb 23; 7(2):247-53. PubMed ID: 8785394
    [Abstract] [Full Text] [Related]

  • 10. Pneumococcal conjugate vaccine primes for polysaccharide-inducible IgG2 antibody response in children with recurrent otitis media acuta.
    Breukels MA, Rijkers GT, Voorhorst-Ogink MM, Zegers BJ, Sanders LA.
    J Infect Dis; 1999 May 23; 179(5):1152-6. PubMed ID: 10191217
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Targeting subcapsular antigens for prevention of Klebsiella pneumoniae infections.
    Clements A, Jenney AW, Farn JL, Brown LE, Deliyannis G, Hartland EL, Pearse MJ, Maloney MB, Wesselingh SL, Wijburg OL, Strugnell RA.
    Vaccine; 2008 Oct 16; 26(44):5649-53. PubMed ID: 18725260
    [Abstract] [Full Text] [Related]

  • 13. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Jackson LA, Gurtman A, Rice K, Pauksens K, Greenberg RN, Jones TR, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B.
    Vaccine; 2013 Aug 02; 31(35):3585-93. PubMed ID: 23688527
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Development of a broad spectrum glycoconjugate vaccine to prevent wound and disseminated infections with Klebsiella pneumoniae and Pseudomonas aeruginosa.
    Hegerle N, Choi M, Sinclair J, Amin MN, Ollivault-Shiflett M, Curtis B, Laufer RS, Shridhar S, Brammer J, Toapanta FR, Holder IA, Pasetti MF, Lees A, Tennant SM, Cross AS, Simon R.
    PLoS One; 2018 Aug 02; 13(9):e0203143. PubMed ID: 30188914
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
    Jackson LA, Gurtman A, van Cleeff M, Jansen KU, Jayawardene D, Devlin C, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B.
    Vaccine; 2013 Aug 02; 31(35):3577-84. PubMed ID: 23688526
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.